Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects (ABL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03719664
Recruitment Status : Recruiting
First Posted : October 25, 2018
Last Update Posted : January 29, 2019
Sponsor:
Information provided by (Responsible Party):
Frontier Biotechnologies Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : October 2020